|
|
||||||||||||||||||||||||||||
|
|
Classification of Interferons |
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|
Two different types of interferons can be described : type I (a, b, w) and type II (g) interferons, which differ in their interaction with distinct cell receptors and induce different biological effects. |
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|
Three main classes of interferons were initially differentiated on the basis of antigenicity, biochemical properties, and producer cell : IFN-a, IFN-b and IFN-g. |
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|
IFN-a and –b, which have been grouped together as type I interferons, bind to the same receptor on the cell surface : the a/b receptor. On the other hand, IFN-g, known as type II interferon, binds to a different receptor, the g receptor. |
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|
In 1985, three groups reported the discovery of a novel type of interferon which is now termed IFN-omega (w). The sequence homology between IFN-w and IFN-a is of about 65% and it has been shown that Hu-IFN-w binds to the a/b receptor. IFN-w is the most recently discovered member of the type I superfamily. It is secreted by cells following viral infection, and displays antiviral, antiproliferative and immunomodulatory activities typical of a type I IFN. |
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|
The human interferon genes and proteins have been extensively studied. There are more than 20 human IFN-a genes but only one IFN-b gene and one single humanIFN-g gene. The major human a IFNs are not glycosylated whereas the b, w and g IFNs are often N-glycosylated. |
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|
IFNs exert their actions through species-specific cell surface receptors. Both the human IFN-a receptor and the human IFN-g receptor have been molecularly cloned between 1988 and 1990. |
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||